throbber
United States Patent [19]
`Lawrence et al.
`
`US005624668A
`Patent Number:
`Date of Patent:
`
`[11]
`
`[45]
`
`5,624,668
`Apr. 29, 1997
`
`[RON DEXTRAN FORMULATIONS
`
`OTHER PUBLICATIONS
`
`P. Carthew et al., Hepatology, vol. 13, No. 3, pp. 534-539
`(1991): Rapid Induction of Hepatic Fibrosis in the Gerbil
`After the Parenteral Administration of Iron-Dextran Com
`pleX.
`L.M. Fletcher, et al., Gastroenterology, vol. 97, pp.
`1011-1018 (1989): Effects of Iron Loading on Free Radical
`scavenging Enzymes and Lipid Peroxidation in Rat Liver.
`R.D. Hamstra et al., JAMA, vol. 243. No. 17, pp. 1726-1731
`(1980): Intravenous Iron Dextran in Clinical Medicine.
`P.A. Henderson et al., Blood, vol. 34, No. 3, pp. 357-375
`(1969): Characteristics of Iron Dextran Utilization in Man.
`T. O. Pitts et al., Nephron, vol. 22, pp. 316-321 (1978):
`Hemosiderosis Secondary to Chronic Parenteral Iron
`Therapy in Maintenance Hemodialysis Patients.
`L. R. Weintraub et al., British Journal of Haematology, vol.
`59. pp. 321-331 (1985): Pathogenesis of Hepatic Fibrosis in
`Experimental Iron Overload.
`Package Insert for INFeD (Iron Dextran Injection, USP).
`Package Insert for Imferon (Iron Dextran Injection, USP).
`1994 ASH Abstract Reproduction Form, 36th Annual Meet
`ing. Nashville, TN (1994): “Pharmacokinetics of Iron Dex
`tran In Iron De?cient Dialysis Patients: Evaluation and
`Comparison of Two Agents”. by D. Van Wyck et al.
`1994 ASH Abstract Reproduction Form, 36th Annual Meet
`ing, Nashville, TN (1994): “Iron Mobilization Early After
`Iron Dextran Infusion in Hemodialysis Patients: Evaluation
`and Comparison of 2 Agents”. by D. Van Wyck et al.
`
`Primary Examiner—Peter F. Kulkosky
`Attorney, Agent, or Firm-Morrison & Foerster LLP
`
`ABSTRACT
`[57]
`Ferric oxyhydroxide-dextran compositions for treating iron
`de?ciency having ellipsoidal particles with a preferred
`molecular Weight range of about 250,000 to 300,000 dal
`tons.
`
`28 Claims, 6 Drawing Sheets
`
`[54]
`
`[75]
`
`Inventors: Richard P. Lawrence, Baiting Hollow;
`Ralf A. Lange, Amagansett; Chin Wu,
`Shirley; Mary J. Helenek, Syosset, all
`of N.Y.
`
`[73]
`
`Assignee: Luitpold Pharmaceuticals, Inc.,
`Shirley, N.Y.
`
`[21]
`[22]
`[5 1]
`[52]
`[53]
`
`[5 6]
`
`Appl. No.: 536,984
`Filed:
`Sep. 29, 1995
`
`Int. Cl.6 .......................... .. A01N 59/16; A61K 33/26
`US. Cl. ....................................... .. 424/7817; 424/647
`Field of Search ................................... .. 424/421, 647.
`424/7817
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`Re. 24,642
`2,820,740
`2,885,393
`3,686,397
`3,697,502
`3,908,004
`4,101,435
`4,180,567
`4,452,773
`4,454,773
`4,505,726
`4,599,405
`4,659,697
`4,749,695
`4,788,281
`4,927,756
`5,102,652
`5,118,513
`5,248,492
`5,336,506
`5,354,350
`
`4/1959
`1/1958
`5/1959
`8/1972
`10/1972
`9/1975
`7/1978
`12/1979
`6/1984
`6/1984
`3/1985
`7/1986
`4/1987
`6/1988
`11/1988
`5/1990
`4/1992
`6/1992
`9/1993
`8/1994
`10/1994
`
`London at al. .
`London et al. .
`
`Herb .
`
`Muller .
`
`Christensen .
`Kitching .
`Hasegawa et a1. .
`Herb .
`Molday ................................. .. 436/526
`Brunner et al. .
`Takeuchi et al. .
`Muekker et al. .
`
`Tanaka .
`Schwengers .
`Tosoni et al. .
`Schwengers .
`Groman et al. ,
`Mehansho et al. .
`Groman et al. .
`Josephson et al. ,
`Moore .
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`Luitpold Pharmaceuticals, Inc., Ex. 2054, P. 1
`
`

`
`US. Patent
`
`Apr. 29, 1997
`
`Sheet 1 of 6
`
`5,624,668
`
`_ _
`
`oodw
`OOdN
`
`p
`
`p h
`
`8552
`
`_
`
`oosvm
`QQNN
`006m
`
`00
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`Luitpold Pharmaceuticals, Inc., Ex. 2054, P. 2
`
`

`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`Luitpold Pharmaceuticals, Inc., Ex. 2054, P. 3
`
`

`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`Luitpold Pharmaceuticals, Inc., Ex. 2054, P. 4
`
`

`
`US. Patent
`
`Apr. 29, 1997
`
`Sheet 4 0f 6
`
`5,624,668
`
`_ _ _ _ _ _ _ _ b _ _ _ _ _ P _ _ _ _ _ _ _ p P _ r _ _ _
`
`
`
`
`
`
`
`
`
`
`
`
`
`006m oodm 006w 006w OQNN 00.0w oo.w—
`
`lllllllllTl
`I
`o
`o.
`co
`N
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`Luitpold Pharmaceuticals, Inc., Ex. 2054, P. 5
`
`

`
`U S Patent
`
`Apr. 29, 1997
`
`Sheet 5 of 6
`
`5,624,668
`
`FIG, 5
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`Luitpold Pharmaceuticals, Inc., Ex. 2054, P. 6
`
`

`
`US. Patent
`
`Apr. 29, 1997
`
`Sheet 6 0f 6
`
`5,624,668
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`Luitpold Pharmaceuticals, Inc., Ex. 2054, P. 7
`
`

`
`5,624,668
`
`1
`IRON DEXTRAN FORMULATIONS
`
`FIELD OF THE INVENTION
`
`The present invention relates to improved iron dextran
`formulations for the treatment of iron de?ciency, and to
`methods for preparing such formulations.
`
`BACKGROUND OF THE INVENTION
`
`The intravenous or intramuscular injection of sterile solu
`tions of an iron dextran complex is clinically indicated for
`the treatment of patients with documented iron de?ciency in
`whom oral administration is unsatisfactory or impossible.
`Iron dextran is absorbed from the injection site after
`intramuscular injection, for example. into the capillaries and
`the lymphatic system Circulating iron dextran is cleared
`from the plasma by cells of the reticuloendothelial system,
`which split the complex into its components of iron and
`dextran. IMFERON®. for example. a product previously
`marketed by Fisons Pharmaceuticals. is released to the blood
`after uptake by the phagocytic activity of macrophages. See
`Henderson. et al., Blood 34:357-375 (1969). The iron
`immediately is bound to available protein moieties to form
`hemosiderin or ferritin. the physiological forms of iron or, to
`a lesser extent. to transferrin. This iron. which is subject to
`physiological control, replenishes the iron component of
`hemoglobin and other depleted iron stores.
`The major bene?t of the clinical use of iron dextran is that,
`due to its large molecular weight (i.e.. greater than 70,000
`daltons). the iron dextran complex is not excreted by the
`kidneys. Therefore almost the entire dose of iron dextran
`remains bioavailable as the iron dextran is metabolized in
`the liver. The major portion of an intramuscular injection of
`iron dextran is absorbed within 72 hours. Most of the
`remaining iron is absorbed over the ensuing 3 to 4 weeks.
`Iron dextran for parenteral administration currently is
`marketed by Steris Pharmaceuticals, Inc. under the brand
`name lNFeD®. As formulated. this product is a dark brown
`and slightly viscous sterile liquid complex of ferric
`oxyhydroxide. beta-FeO(OH). and is a low molecular
`weight dextran derivative in approximately 0.9% weight per
`volume sodium chloride for intravenous or intramuscular
`use. It contains the equivalent of 50 mg of elemental iron (as
`an iron dextran complex) per ml. Sodium chloride may be
`added for tonicity. The pH of the solution is between 5.2 and
`6.5.
`Under electron microscopy, IMFERON® has been shown
`to have an inner electron-dense FeO(OH) core with a
`diameter of approximately 3 nm and an outer moldable
`plastic dextran shell with a diameter of approximately 13
`nm. Almost all of the iron. about 98-99% is present as a
`stable ferric-dextran complex. The remaining iron represents
`a very weak ferrous complex.
`The dextran component of conventional iron dextran
`products is a polyglucose that either is metabolized or
`excreted Negligible amounts of iron are lost via the urinary
`or alimentary pathways after administration of iron dextran.
`Staining from inadvertent deposition of iron dextran in
`subcutaneous and cutaneous tissues usually resolves or fades
`within several weeks or months. Various studies have
`reported that the half life of iron dextran in iron de?cient
`subjects ranges from 5 to more than 20 hours. Notably. these
`half-life values do not represent clearance of iron from the
`body because iron is not readily eliminated from the body.
`See. for example. the package inserts for IMFERON® and
`INFeD®. or Hamstra, et al. JAMA 24321726-1731 (1980).
`
`15
`
`25
`
`35
`
`45
`
`55
`
`65
`
`2
`U.S. Pat. No. 2,820,740 and its reissue RE 24,642 to
`London et al. describe colloidal injectable iron preparations
`suitable for parenteral injection formed of a nonionic ferric
`hydroxide, partially depolymerized dextran complex. Cur
`rent commercial iron dextran products, based on these two
`prior patents do not have su?icient purity (see FIGS. 1 and
`2) and needed thermal stability (see FIGS. 3 and 4) to
`safeguard safety and sterility concerns. Also, these commer
`cial products have a relatively short plasma residence time
`which could cause a potential risk of iron overload in
`speci?c organs. See, Carthew. R. E. . et al. Hepatology 13 (3)
`:534-538 (1991); Pitts, T. 0., et al. Nephron 22:316 (1978);
`Weintraub, L. R., et al. Brit. J. Hematology 59:321 (1985);
`and Fletcher, L. M., et al., Gastroenterology 97:1011 (1989).
`Similarly, U.S. Pat. No. 2,885.393 to Herb also discloses
`iron dextran complexes. The most suitable range in molecu
`lar weight of the partially depolymerized dextran for injec
`tion was found to be 30,000 to 80,000 daltons or lower. A
`subsequent patent to Herb, U.S. Pat. No. 4,180,567, dis
`closes other iron preparations and methods for making and
`administering such preparations; however, the method dis
`closed does not teach the heating of iron dextran complexes
`above 100° C.
`Other methods for the production of iron dextran com
`plexes have been described, for example, in U.S. Pat. No.
`4,599,405 to Muller et al. regarding iron (IlI) hydroxy/
`dextran complexes that are produced using an alkali
`carbonate, ammonium carbonate or a carbonate of an
`organic base added to an acid solution containing a partially
`depolymerized dextran and an iron (111) salt. Thereafter, an
`alkali metal hydroxide or ammonium hydroxide is added.
`The suspension so formed is then converted into a solution
`by heating, and the solution worked up in a known manner.
`Alternatively, ferric chloride and dextran can be reacted in
`aqueous solution in the presence of citric acid as disclosed
`in U.S. Pat. No. 3,697,502 or by treating reactive trivalent
`iron with a complex-forming agent consisting of sorbitol,
`gluconic acid and certain oligosaccharides, in particular
`proportions and amounts as taught in U.S. Pat No. 3,686,
`397.
`U.S. Pat. No. 4,749,695 and its divisional, U.S. Pat. No.
`4,927,756. both to Schwengers, disclose a water-soluble iron
`dextran and a process for its manufacture. As disclosed, the
`dextran utilized has an average molar mass of from 2,000 to
`4,000 daltons. Another alternative includes the complex
`ation of ferric hydroxide with hexonic acid derivatives of
`dextran as in U.S. Pat. No. 4,788,281 to Tosoni.
`U.S. Pat. No. 3,908,004 to Kitching discloses the prepa
`ration of iron compositions to treat iron-de?ciency anemia.
`Methods of formulating these compositions include the
`heating of an aqueous alkaline solution of a polysaccharide
`with a water soluble inorganic iron compound such as ferric
`oxychloride. The presence of the alkali is said to be neces
`sary to bring about the formation of the complex. However,
`the alkaline conditions also cause some degradation of the
`polysaccharide and the low molecular-weight species so
`formed produce iron compounds which are responsible for
`undesirable effects.
`U.S. Pat. No. 4,659,697 to Tanaka discloses a process for
`producing an organoiron (II) compound-containing antiane
`mic composition which through the cultivation of a yeast in
`a saccharide-containing nutrient medium, such as grape
`juice, in the presence of an iron compound to form a cultured
`broth comprising an organoiron(lI) compound, alcohol and
`water and removing the alcohol from the cultured broth to an
`extent that the resulting cultured broth has an alcohol
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`Luitpold Pharmaceuticals, Inc., Ex. 2054, P. 8
`
`

`
`3
`content of less than about 1% by volume, and an antianemic
`composition produced thereby. The antianernic composition
`was said to be very stable, with excellent absorbability into
`a living body and incorporation of iron into hemoglobin.
`Iron dextran complexes also have application as imaging
`agents. For example, dextran/magnetite is disclosed as a
`particulate solution speci?cally noted to be stabilized by
`polymeric dextran. (See Hasegawa et al.. U.S. Pat. No.
`4.l01,435. Several others have used dextrans of various
`molecular weights as ingredients in the synthesis of mag
`netic colloids or particles. (See Hasegawa et al., U.S. Pat.
`No. 4.101.435; Molday, US. Pat. No. 4,454,773; and
`Schroder, US. Pat. No. 4.505.726. The resulting complexes
`of dextran and iron oxide have varying sizes and structures,
`but all have molecular weights of at least about 500,000
`daltons.
`The incorporation of high molecular weight dextran into
`magnetic particles or colloids may, however, cause some
`patients to experience adverse reactions to the dextran,
`particularly when such complexes are administered as
`parenteral magnetic resonance contrast agents. These
`adverse reactions may also be due in part to problems of
`high molecular weight polymers such as dextran dissociat
`ing from the metal oxide colloid upon prolonged storage or
`under high temperatures,'thereby leaving the metal oxide
`free to aggregate.
`Despite the variety of iron dextran formulations described
`in the prior act. current iron de?ciency products are based on
`technology that has not satisfactorily resolved stability and
`purity concerns. What is needed in the therapeutic ?eld of
`iron supplementation. is an improved next-generation iron
`dextran product with enhanced purity and thermal stability,
`as well as prolonged plasma residence time to minimize
`possible iron overload complications without compromising
`the e?icacy of iron dextran therapy.
`SUMMARY OF THE INVENTION
`These and other objects are achieved by the iron dextran
`product prepared according to this invention. It has excellent
`attributes and thermal stability but also has prolonged
`plasma residence time to minimize possible iron overload
`problem without compromising the e?icacy of iron dextran.
`It is an object of the present invention to provide methods
`for synthesizing iron dextran compositions useful in the
`treatment of iron de?ciency. Associated compositions also
`are disclosed. Such compositions include aqueous colloidal
`suspensions or solutions of a ferric oxyhydroxide-dextran
`complex, having an average molecular weight of about
`100,000 to 600,000 daltons and a substantially uniform size
`distribution. Physiologically acceptable carriers for these
`compositions also are contemplated. The administration of
`such compositions to humans and other mammals for the
`treatment of iron de?ciency or, in the case of non-human
`mammals. for medicinal as well as investigational purposes
`also are described.
`In a preferred embodiment of the present invention, the
`molecular weight range of the iron dextran compositions are
`about 150.000 to 350,000 daltons, and more particularly
`preferred are compositions with a molecular weight range of
`about 250.000 to 300.000 daltons.
`It is a further object of the present invention to provide
`iron dextran compositions having a beta-FeO(OH) core. A
`further object of the invention is to provide ellipsoidal
`iron-dextran particles with a length in the range of about 25
`to 45 nanometers, more preferably about 31.5 to 36.5
`nanometers, and a width of about 3.5 to 5.5 nanometers,
`more preferably about 4 to 5 nanometers.
`
`4
`It is a further object of the present invention to provide
`methods for synthesizing iron-dextran compositions as
`described above. The process of the present invention
`involves the initial production of iron-dextran particles by
`conventional methods. Applicants, however, have discov
`ered that superior particles may be produced by the follow
`ing process. Generally, as discussed in greater detail below,
`iron-dextran particles are puri?ed by conventional tech
`niques to remove various impurities, in particular, chloride
`iron, but also including any toxic by-products. uncomplexed
`dextran and, generally, any component of the initial iron
`dextran reaction mixture which would not be appropriate or
`permitted to be administered to patients in an approvable
`composition.
`
`BRIEF DESCRIPTION OF THE DRAWING
`FIGURES
`
`FIG. 1 shows a HPGPC chromatograrn of an iron dextran
`formulation according to the present invention demonstrat
`ing its uniform molecular weight distribution.
`FIG. 2 shows the HPGPC chromatogram of two commer
`cial preparations of iron dextran demonstrating a signi?cant
`heterogeneity relative to the formulations in FIG. 1.
`FIG. 3 shows the HPGPC chromatogram of an iron
`dextran formulation according to the present invention
`assessed over a period of seven days, demonstrating the
`stability of formulations.
`FIG. 4 shows the HPGPC chromatograrn of a commercial
`iron dextran formulation assessed over a period of seven
`days, demonstrating a signi?cant instability relative to the
`formulation of FIG. 3. At a magni?cation of 140,000 times.
`FIG. 5 shows that an electron photomicrograph of iron
`dextran particles according to the present invention at a
`magni?cation of 140,000><.
`FIG. 6 shows electron photomicrograph of particles sold
`under the brand name INFeD® at a magni?cation of 140,
`000x.
`
`DESCRIPTION OF THE PREFERRED
`EMBODIMENTS
`The present inventors have found that iron dextran for
`mulations prepared according to the following speci?cations
`are surprisingly more temperature stable and/or exhibit a
`much greater degree of homogeneity than is evidenced by or
`would have been expected from iron dextran formulations of
`the prior art such as IMFERON® and INFED®. The
`improved methods and compositions disclosed for the
`preparation of these iron dextran formulations achieve uni
`form molecular weight distribution. Safety, reliability and
`quality of iron dextran injectable and infusible products can
`be signi?cantly improved over previous products. Our prod
`uct now in development is called DEEG'ERRUM®. DEX
`FERRUM® is a pharmaceuticaJly-equivalent iron dextran
`characterized by a higher mean molecular weight (266,
`608i1.4% daltons).
`In the following discussion and examples, certain calcu
`lations as set forth below are required to determine the
`amounts of active and inactive ingredients:
`The amount of iron dextran is based on its iron (Fe
`content. The amount in mg/ml is calculated by dividing the
`desired iron concentration in mg/ml of elemental iron by the
`powder’s % w/w iron content divided by 100. This amount
`is then multiplied by the batch size in liters for the amount
`required in grams for that batch size. This value is then
`corrected for its moisture content.
`
`5,624,668
`
`25
`
`35
`
`40
`
`45
`
`50
`
`55
`
`65
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`Luitpold Pharmaceuticals, Inc., Ex. 2054, P. 9
`
`

`
`5,624,668
`
`15
`
`25
`
`5
`In general. a suitable iron 1]] salt, such as ferric chloride,
`is neutralized with a suitable alkali to which a modi?ed
`dextran is added either before. concomitantly or after neu
`tralization to produce an iron dextran complex with a
`molecular weight in the range of about 100,000 to about
`600.000 daltons. The resulting solution is puri?ed of excess
`dextran, salts. toxic impurities, etc., such as are identi?ed in
`Table 2 by any suitable method to produce an iron dextran
`aqueous concentrate or powder with an elemental iron
`concentration of between about 5% to about 50%. Puri?ed
`iron dextran powder or concentrate is then used in the
`preparation of a ?nal solution made of the foregoing iron
`dextran composition, with an elemental iron content of
`about 25 to about 100 mg/ml.
`We have observed that in solution. dextran is not tightly
`bound to the iron core, and complexes formed of aggregates
`in which. e.g.. two cores might be bound to the same dextran
`molecule. can be observed. The dextran serves to stabilize
`the core. but the puri?cation process associated with the
`initial preparation of iron dextran particules in which. e.g.,
`chloride iron is removed, also tends to remove some of the
`dextran.
`To a ?nal solution made of the foregoing iron-dextran
`composition. an appropriate amount of oxidized dextran is
`added to provide a desired ?nal ratio of the content of iron
`to dextran in the ?nal iron dextran composition in a range
`from about 1:2 to 1:5. but preferably about 1:4 as described
`in greater detail below. The iron-dextran and oxidized dex
`tran mixture is heated and reacted for an appropriate length
`of time with a suitable alkali. Generally, an appropriate
`length of time is not less than about one hour. The actual
`amount of time required to complete the reaction is depen
`dent on the amounts and ratios of starting materials. Deter
`mination of the end point may be measured by the absence
`of dextran enhancement of the LAL endotoxins test. We
`35
`have determined that oxidized dextran enhances the LAL gel
`clot method for assessing endotoxins, whereas reacted
`material. prepared according to our disclosure, demonstrates
`no such enhancement. Thus. in our manufacturing
`procedure, the reaction end point is determined by this
`technique to be complete when the amount of unreacted
`dextran does not exceed about 0.05 percent. After cooling
`and dilution to a ?nal volume, the pH of the solution is
`adjusted to a physiologically acceptable pH range. This
`adjusted solution is then aseptically ?lled and/or terminally
`sterilized for administration, such as by injection.
`We believe that the reaction of the iron dextran complex
`with an oxidized dextran under alkaline conditions converts
`the terminal unit of oxidized dextran from fS-Gluconolactone
`to sodium gluconate. The resulting solution contains dextran
`that is both bound and unbound to the iron complex where
`the molecular weight distributions of the bound and
`unbound dextrans are in equilibrium. Without wishing to be
`bound by any particular mechanism of action. we believe
`that the oxidized dextran at this stage of processing of iron
`dextran compositions minimizes or substantially eliminates
`aggregate complexes in which two iron cores might be
`bound to the same dextran molecule. Moreover. oxidized
`dextran has a terminal carboxyl group and has superior
`chelating abilities.
`The amount of oxidized dextran required to produce the
`desired product meeting its desired nonvolatile residue is
`calculated by subtracting the calculated # mg/ml iron dex
`tran (dry weight) from the theoretical total weight based on
`the nonvolatile residue of the desired product. That is. for a
`nonvolatile residue of 28-43 % w/v. the theoretical total
`weight would range from 280 to 430 mg/ml. The value
`
`6
`obtained is then corrected for the oxidized dextran’s loss on
`drying by dividing this value by (l-(loss on drying/100)).
`This amount is then multiplied by the batch volume in liters
`for the amount of grams for that batch size.
`The amount of alkali (such as sodium hydroxide) is
`dependent on the amount of oxidized dextran since it reacts
`with the alkali to form a carboxylic acid. The reaction is 1: 1.
`To determine the appropriate amount of alkali (such as
`NaOH) in grams, the molecular weight of the alkali is
`multiplied by the number of grams of oxidized dextran
`required for the desired product which is then divided by the
`average molecular weight of the oxidized dextran.
`A maximum limit for the hydrochloric acid used to adjust
`pH is calculated using the desired product’s upper limit for
`chloride content. The amount of chloride supplied by the
`starting materials (iron dextran and oxidized dextran) is
`calculated, then the maximum amount of hydrochloric acid
`added is determined by subtracting the total amount of
`chloride supplied from the starting materials from the
`desired product’s upper limit for chloride content, then
`multiplying the value obtained by the batch size in liters,
`divide this value by the atomic weight of chloride (35.5) and
`then divide by the normality of the hydrochloric acid solu
`tion to be used for the ?nal value.
`The low molecular weight carbohydrates of the invention
`must be oxidized in order to avoid problems in lack of
`uniformity and with the presence of endotoxins. Such car
`bohydrates preferably have a molecular Weight in the range
`of about 2,000 to 15,000 daltons, most preferably around
`6,000 to 7,000 daltons. The preferred concentrations of the
`carbohydrates of the invention which effectively impart
`stabilization to the carrier phase of the metal oxide compo
`sition are in the range of about 0.001M to about 2M, most
`preferably about 0.05M to about 0.5M, but optimal concen
`trations can be determined by those skilled in the art
`according to conventional techniques.
`Some preferred low molecular weight stabilizing agents
`include. but are not limited to, mannitol, sorbitol, glycerol,
`inositol, dextran 1 (Pharmacia Inc., Piscataway, NJ.) and
`ascorbate. Other useful agents include dextrins, celluloses,
`hydroxyethylstarches, heparins, starches, dextran sulfates,
`carboxylmethylated dextran and carboxymethyl cellulose.
`In the case of dextran 1, which has a molecular weight of
`about\1,000 daltons, the same compound can both stabilize
`the colloid or particulate suspension against unwanted
`physical changes and block possible adverse reactions. The
`simultaneous injection of dextran 1 and a complex of
`dextran and the magnetic iron oxide decreases adverse
`reactions to high molecular weight dextran alone.
`Preferred methods of manufacture of iron dextran solu
`tions involve the neutralization of ferric chloride solution
`with an alkaline solution of dextran. The mixture is heated,
`then cooled to room temperature and clari?ed by centrifu
`gation. The resulting solution is then concentrated to the
`desired iron content by dialysis against running water. The
`iron dextran is composed of a beta-FeO(OH) core formed by
`the neutralization of an acidic ferric chloride/dextran solu
`tion with alkaline sodium bicarbonate. The by-products of
`this reaction are sodium chloride and carbon dioxide. During
`neutralization. the modi?ed dextran is absorbed (complexes)
`to the iron core’s surface where the dextran’s hydroxyl
`groups provide the “OH” needed for stabilization of the
`core’s beta-FeO(OH) structure.
`
`50
`
`55
`
`65
`
`EXAMPLES
`
`Experimental studies describing the use of low molecular
`Weight carbohydrates as stabilizing agents for metal oxide
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`Luitpold Pharmaceuticals, Inc., Ex. 2054, P. 10
`
`

`
`5,624,668
`
`7
`compositions prepared according to the present invention
`are presented below. These examples are to be considered as
`illustrative of the present invention rather than lirnitative of
`its scope in any way.
`The preferred dextran formulation for the production of
`iron dextran formulations according to the present invention
`are prepared by fermentation of sucrose using Ieuconostoc
`mesenteroides bacteria (NRRL B-512 (F)). The crude dex
`tran is precipitated, hydrolyzed. and fractionated by conven
`tional means. The dextran fraction is oxidized with an
`oxidizing agent under alkaline conditions, then puri?ed.
`Studies on the structure of the iron dextran complex report
`that it is composed of a beta-FeO(OH) core complexed with
`low molecular weight dextrans ranging from 3,500 to 7,500
`daltons. The oxidized dextran used in this invention is the
`dextran which is depolymerized to an average molecular
`weight ranging from 3.500 to 7,500 daltons. The dextran’s
`terminal unit. D-glucose. is then oxidized to gluconolactone.
`During the manufacturing process described in this inven
`tion the oxidized deXtIan’s terminal unit, gluconolactone, is
`converted to D-glucuronic acid via alkaline hydrolysis.
`The oxidized dextran used to produce iron dextran prod
`ucts according to the present invention has the following
`physical properties as set forth in Table 1:
`
`5
`
`10
`
`15
`
`20
`
`25
`
`TABLE 1
`
`Parameter
`
`Tolerance
`
`Description
`odor
`Loss on Drying (w/w %)
`Sodium chloride content
`(w/W %)
`Nitrogenous Impurities
`Bromide content
`Alcohol and Related
`Impurities
`Relative Viscosity of a 10
`% sol
`Average Molecular Weight
`Phosphate (w/w %)
`Reducing Sugars (w/w %)
`Pyrogen Test
`
`White, amorphous powder
`Odorless
`Not more than 5.0%
`Not more than 2.0%
`
`Not more than 0.015%
`Less than 5 ppm
`Less than 0.05% w/w
`
`Less than 4.0 centistokes
`
`Between 3,000 and 7,000
`Not more than 0.28%
`Not more than 7.0%
`Passes test
`
`The characteristics and physical properties of the pre
`ferred iron dextran powder used to produce iron dextran
`formulations of the present invention are as follows in Table
`2. This composition is commercially available from Labo
`ratorien Hausmann AG in Switzerland, and U.S. Pat. No.
`4.599.405, discussed above. is relevant to the preparation of
`such compositions. U.S. Pat. No. 3,697,502 also is relevant.
`
`TABLE 2
`
`Parameter
`
`Tolerance
`
`Description
`Identi?cation
`Loss on Drying (w/w %)
`Sodium chloride content
`
`Brown, amorphous powder
`Complies
`Not more than 10.0%
`Not more than 6.0%
`
`Dextran content
`Iron Content
`Bromide content
`Alcohol and Related
`Impurities
`pH of a 5% Solution
`Molecular Weight
`Determination by GPC
`
`Between 29.0 and 36.0%
`Between 28.0 and 35.0%
`Less than 5 ppm
`Less than 0.05% w/w
`
`5.2 to 6.5
`
`Mw
`Mn
`
`Between 255,000-520,000
`Between 200,000-365,000
`
`TABLE 2-continued
`
`Parameter
`
`Tolerance
`
`MWJMl1
`Arsenic
`Lead
`Copper
`Zinc
`Bacterial Endotoxins
`
`Not more than 1.7
`Not more than 2 ppm
`Not more than 100 ppm
`Not more than 100 ppm
`Not more than 100 ppm
`Passes test
`
`EXAMPLE 1
`Preparation of Iron dextran Compositions
`In a 200 liter steam-jacket reaction vessel, 114 liter of hot
`(70° C. —90° C.) water was added. Next, 30.0 kg of iron
`dextran, satisfying the parameters described above, along
`with 28.3 kg oxidized dextran, also satisfying the parameters
`discussed above. The mixture was diluted up to 175 liters.
`Next. 185 g of NaOH was added and mixed with the iron
`dextran mixture. The vessel was sealed and then heated to a
`range of 110° C.—1l5° C. using a steam jacket for three
`hours. The vessel was then cooled to approximately 25° C.
`and vented during the cooling process. The pH was tested
`and adjusted to the range of 5.7-6.0.
`The reaction solution was pre?ltered through a 1.0 micron
`membrane into a holding vessel. Next, the ?ltered solution
`was passed through a 0.2 micron ?lter into sterilized receiv
`ing vessels. and depyrogenated vials were ?lled and stop
`pered with aliquots of the sterilized solution.
`
`EXAMPLE 2
`
`35
`
`45
`
`50
`
`55
`
`60
`
`65
`
`Evaluation of Process Results to Determine Molecular
`Weight Using HP-GPC
`The molecular Weight of the iron dextran complex of
`Example 1 was determined by gel permeation chromatog
`raphy in a'HP-GPC system equipped with a differential
`refractometer as the detector and an integrator with a GPC
`program for molecular weight calculations. The HP-GPC
`column was packed with porous particles of polyacrylic acid
`containing pore sizes up to 1000 angstroms. The pores act as
`sieves where smaller molecules permeate through in the
`pacln'ng’s pores while the larger molecules are excluded
`from the packing and are eluted by the more mobile phase.
`Thus, macromolecules elute from the columns, from largest
`to smallest.
`FIGS. 1-4 show comparisons between the iron dextran
`formulations of the present invention and two commercial
`preparations. These ?gures present data generated by a
`refractive index detector. This detector measures the con
`centration of the iron dextran, dextran and other molecules
`and the integrator’s GPC program interprets the data and
`calculates the relative: weight average molecular weight
`(MW), number average molecular weight (Mn) and polydis
`persity index (MW/Mn) of the sample. The reported values
`are based on polyethyleneglycol (PEG) and polyethylenox
`ide (PEO) standards used for calibration of the instrument,
`and are considered relative molecular weights which should
`be within 5% of the actual values.
`Ellipsoidal particles of the present invention are shown in
`FIG. 5. This shows DE)G1ERRUM® at a magni?cation of
`about 140.000X. In comparison. FIG. 6 shows particles sold
`under the name INFeD®. The unique conformation and
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`Luitpold Pharmaceuticals, Inc., Ex. 2054, P. 11
`
`

`
`5,624,66

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket